Overview

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Status:
Completed
Trial end date:
2020-02-13
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Carboplatin
Cisplatin
Gemcitabine